Analysts Set Xencor, Inc. (NASDAQ:XNCR) PT at $28.00

Key Points

• Xencor, Inc. has received a consensus rating of "Moderate Buy" from eight brokerages, with one sell rating and seven buy ratings; the average target price among analysts is $28.00.
• The company reported a revenue of $32.73 million for the quarter, significantly higher than the consensus estimate of $23.44 million, despite an earnings per share loss of ($0.66).
• Insiders have sold a total of 15,810 shares in the last three months, raising concerns with a decrease of 12.91% and 13.50% in their positions by two directors.

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $28.00.

Several research firms have recently weighed in on XNCR. William Blair began coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating on the stock. Wedbush reaffirmed an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Finally, Barclays reduced their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th.

Insider Transactions at Xencor

In related news, Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares in the company, valued at $176,867.26. This represents a 13.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director owned 19,183 shares of the company's stock, valued at $176,867.26. This trade represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,810 shares of company stock valued at $154,123 over the last 90 days. Insiders own 4.76% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. RTW Investments LP increased its position in Xencor by 317.9% in the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock worth $55,218,000 after purchasing an additional 1,827,883 shares during the last quarter. BVF Inc. IL increased its holdings in shares of Xencor by 169.3% during the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock valued at $52,596,000 after acquiring an additional 1,438,760 shares during the last quarter. Braidwell LP increased its holdings in shares of Xencor by 169.0% during the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company's stock valued at $17,617,000 after acquiring an additional 1,040,159 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Xencor by 8.6% during the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company's stock valued at $103,857,000 after acquiring an additional 776,580 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in shares of Xencor by 452.4% during the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock valued at $19,236,000 after acquiring an additional 685,557 shares during the last quarter.

Xencor Price Performance

Xencor stock traded down $0.34 during midday trading on Monday, reaching $8.40. 98,631 shares of the company were exchanged, compared to its average volume of 760,284. The company has a market capitalization of $597.47 million, a price-to-earnings ratio of -2.75 and a beta of 0.85. The firm's 50-day simple moving average is $8.66 and its 200-day simple moving average is $11.58. Xencor has a 1 year low of $7.16 and a 1 year high of $27.24. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The business had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. During the same period in the previous year, the business posted ($1.11) earnings per share. The firm's quarterly revenue was up 104.6% on a year-over-year basis. On average, analysts anticipate that Xencor will post -3.68 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.